MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...

Citing people familiar with the matter, the report suggested two companies have been negotiating with Cidara over a sale, and ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Greetings. Welcome to the PDS Biotechnology Corporation’s Third Quarter 2025 Earnings Conference Call. At this time, all participants are ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced ...

Merck , known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell ...

MONTREAL, Nov. 13, 2025 /CNW/ – Myeloma Canada welcomes the Canadian Drug Agency’s (CDA) two positive recommendations for the ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third ...

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company or Cidara), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc ...